Gamco Investors INC. ET AL Sells 10,368 Shares of Pacific Biosciences of California (NASDAQ:PACB)

Gamco Investors INC. ET AL trimmed its stake in Pacific Biosciences of California (NASDAQ:PACB) by 2.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 447,588 shares of the biotechnology company’s stock after selling 10,368 shares during the period. Gamco Investors INC. ET AL’s holdings in Pacific Biosciences of California were worth $2,310,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. LPL Financial LLC lifted its stake in shares of Pacific Biosciences of California by 39.3% during the 2nd quarter. LPL Financial LLC now owns 28,350 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 8,000 shares during the last quarter. Syquant Capital Sas lifted its stake in shares of Pacific Biosciences of California by 43.6% during the 2nd quarter. Syquant Capital Sas now owns 712,227 shares of the biotechnology company’s stock worth $4,309,000 after acquiring an additional 216,101 shares during the last quarter. Boston Private Wealth LLC bought a new stake in shares of Pacific Biosciences of California during the 2nd quarter worth approximately $115,000. Aperio Group LLC lifted its stake in shares of Pacific Biosciences of California by 20.3% during the 2nd quarter. Aperio Group LLC now owns 76,246 shares of the biotechnology company’s stock worth $461,000 after acquiring an additional 12,844 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its stake in shares of Pacific Biosciences of California by 63.0% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 75,000 shares of the biotechnology company’s stock worth $451,000 after acquiring an additional 29,000 shares during the last quarter. 70.11% of the stock is owned by institutional investors and hedge funds.

NASDAQ PACB traded down $0.18 on Friday, reaching $4.69. 2,543,200 shares of the stock traded hands, compared to its average volume of 1,647,294. Pacific Biosciences of California has a 12 month low of $4.37 and a 12 month high of $7.84. The company has a fifty day moving average price of $5.09 and a 200-day moving average price of $5.94. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.65 and a current ratio of 2.00. The company has a market cap of $743.41 million, a price-to-earnings ratio of -6.17 and a beta of 1.68.

Pacific Biosciences of California (NASDAQ:PACB) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.04). Pacific Biosciences of California had a negative return on equity of 106.36% and a negative net margin of 140.68%. The business had revenue of $21.92 million for the quarter, compared to analysts’ expectations of $28.02 million. As a group, research analysts anticipate that Pacific Biosciences of California will post -0.65 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on the company. ValuEngine raised Pacific Biosciences of California from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. BidaskClub lowered Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 29th. Finally, Piper Jaffray Companies raised Pacific Biosciences of California from a “neutral” rating to an “overweight” rating and set a $8.00 price target for the company in a research note on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. Pacific Biosciences of California presently has a consensus rating of “Hold” and an average target price of $8.00.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Recommended Story: Options Trading – What is a Straddle?

Want to see what other hedge funds are holding PACB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacific Biosciences of California (NASDAQ:PACB).

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.